Chemical compounds

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Friday, July 9, 2021
Pharmaceutical, Health, Other Health, Drugs, Orphan drugs, Clinical medicine, Chemical compounds, Carfilzomib, Epoxides, Morpholines, Peptides, Multiple myeloma, Proteasome inhibitor, Breakthrough therapy, Daratumumab, Multiple Myeloma, KYPROLIS® (carfilzomib) for injection, BeiGene, MULTIPLE MYELOMA, KYPROLIS® (CARFILZOMIB) FOR INJECTION, BEIGENE

The approval of KYPROLIS provides us with an important opportunity to offer adult patients in China with relapsed or refractory multiple myeloma a proteasome inhibitor with high selectivity and irreversibility as a treatment option for their disease.

Key Points: 
  • The approval of KYPROLIS provides us with an important opportunity to offer adult patients in China with relapsed or refractory multiple myeloma a proteasome inhibitor with high selectivity and irreversibility as a treatment option for their disease.
  • KYPROLIS is approved in the U.S. for the following:
    as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • KYPROLIS is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS monotherapy.

AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Retrieved on: 
Thursday, July 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Chemical compounds, Kidney cancer, Antineoplastic drugs, Renal cell carcinoma, Orphan drugs, Tivozanib, P110δ, Phosphoinositide 3-kinase inhibitor, FOTIVDA® (tivozanib), AVEO Pharmaceuticals, Inc., FOTIVDA® (TIVOZANIB), AVEO PHARMACEUTICALS, INC.

AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.

Key Points: 
  • AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.
  • AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • FOTIVDA has been shown to significantly reduce regulatory T-cell production in preclinical models.1 FOTIVDA was discovered by Kyowa Kirin.
  • FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021

Retrieved on: 
Thursday, July 8, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Orphan drugs, Drugs, Tyrosine kinase inhibitors, Exelixis, Cyclopropanes, Quinolines, Cabozantinib, Cobimetinib, Daiichi Sankyo, NASDAQ

Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Heilind Electronics Partners with Trafag, Expanding Portfolio of Pressure and Temperature Sensors

Retrieved on: 
Thursday, July 8, 2021
Chemical compounds, Tools, Sensors, Molecules, Measuring instruments, Pressure, Pressure sensor, Thermostat, Sulfur hexafluoride

WILMINGTON, Mass., July 8, 2021 /PRNewswire-PRWeb/ -- Heilind Electronics , a premier distributor of electronic components worldwide, has partnered with Trafag, a global leader in the design and manufacture of harsh environment pressure sensors and transmitters, temperature sensors and SF6 gas density sensors.

Key Points: 
  • WILMINGTON, Mass., July 8, 2021 /PRNewswire-PRWeb/ -- Heilind Electronics , a premier distributor of electronic components worldwide, has partnered with Trafag, a global leader in the design and manufacture of harsh environment pressure sensors and transmitters, temperature sensors and SF6 gas density sensors.
  • Also included in Heilind's Trafag offering are pressure switches and pressostats, thermostats and temperature transmitters, and SF6 gas density monitors and sensors.
  • These products are environmentally friendly and ideal for monitoring the pressure and temperature of fuel in large combustion engines.
  • Trafag Sensors and Controls is one of the world's leading suppliers of high-quality sensors and monitoring devices for pressure, temperature and SF6 gas density.

Global Carbon Capture and Storage Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Oil, Gas, Energy, Carbon capture and sequestration, Chemical compounds, Chemistry, Chemical substances, Carbon capture and storage, Carbon dioxide, Greenhouse gas, Carbon capture, Enhanced oil recovery, Carbon capture and storage in Australia

Carbon Capture and Storage (CCS), is aiding the oil and gas industry to mitigate greenhouse gases out of the atmosphere.

Key Points: 
  • Carbon Capture and Storage (CCS), is aiding the oil and gas industry to mitigate greenhouse gases out of the atmosphere.
  • In other circumstances, the carbon dioxide is not soluble in the oil.
  • Here, injection of carbon dioxide raises the pressure in the reservoir, helping to sweep the oil toward the production well.
  • The United States uses 75% of the global carbon capture capacity in EOR operations, which accounts for nearly 30 Metric ton per annum.

14 - Alpha Demethylase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Organic compounds, Chloroarenes, Pipeline, Dioxolanes, Tertiary alcohols, Imidazoles, Orphan drugs

The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "14-alpha demethylase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-alpha demethylase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different 14-alpha demethylase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • 14-alpha demethylase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

DGAP-News: AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of HSV infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Retrieved on: 
Thursday, July 8, 2021
Chemical compounds, Purines, Organic compounds, Foscarnet, Aciclovir, Chemistry, pritelivir, HSV, AiCuris Anti-infective Cures AG, PRITELIVIR, HSV, AICURIS ANTI-INFECTIVE CURES AG

The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Key Points: 
  • The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
  • Efficacy was also seen in patients who in addition showed resistance or intolerance to foscarnet and had very limited treatment options.
  • In none of the patients, treatment with pritelivir was prematurely discontinued due to adverse events during the trial.
  • Based on the results from the recent US clinical phase 2 trial, AiCuris has started a pivotal phase 3 trial as a basis for NDA submission.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AcelRx, Ocugen, Tarena, and DraftKings and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 8, 2021
Drugs, Chemical compounds, Anilides, General anesthetics, Janssen Pharmaceutica, Piperidines, Analgesics, Sports betting, DraftKings, Sufentanil, Fentanyl, Security

The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

Key Points: 
  • The Company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.
  • misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.
  • For more information on the DraftKings class action go to: https://bespc.com/cases/DKNG
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Biochem Launches Biochem® TEST: A Natural Testosterone Booster

Retrieved on: 
Wednesday, July 7, 2021
Hormones, Organic compounds, Chemical compounds, Androstanes, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators

NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.

Key Points: 
  • NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.
  • Specifically formulated with vitamins, plus natural herbs, TEST helps men feel their best both inside and outside of the bedroom.
  • "Testosterone is a key male sex hormone produced by the human body.
  • Unfortunately, after age 30, most men begin to experience a gradual decline in free testosterone.

Marubeni and Navigator Gas: World's First Carbon Neutral Ethylene Voyage

Retrieved on: 
Wednesday, July 7, 2021
Chemical compounds, Greenhouse gas emissions, Shipping companies, Chemistry, Renewable energy, Carbon finance, Carbon dioxide, Navigator Gas, Carbon neutrality, Marubeni, Carbon offset

LONDON, July 7, 2021 /PRNewswire/ -- Marubeni Corporation ("Marubeni") and Navigator Holdings Ltd. ("Navigator Gas"), the owner and operator of the world's largest fleet of handysize liquefied gas carriers, today announce that they will achieve an environmental milestone with the world's first carbon neutral ethylene voyage.

Key Points: 
  • LONDON, July 7, 2021 /PRNewswire/ -- Marubeni Corporation ("Marubeni") and Navigator Holdings Ltd. ("Navigator Gas"), the owner and operator of the world's largest fleet of handysize liquefied gas carriers, today announce that they will achieve an environmental milestone with the world's first carbon neutral ethylene voyage.
  • Marubeni and Navigator Gas will ensure this voyage is carbon neutral through offsetting the CO2 emissions[1] from the voyage by investing in an environmental project in Cambodia designed to reduce emissions from deforestation and forest degradation.
  • Due to the increasing customer requirements for low carbon and carbon neutral solutions, Marubeni intends to further develop this service for its customers.
  • "We are happy to achievethefirst ever carbon neutral ethylene voyage together with Navigator Gas.